



## Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

August 25, 2025

CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- [Beam Therapeutics Inc.](#) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

- Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m. ET in Boston
- 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025, at 1:30 p.m. ET in Boston
- H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference on Monday, September 8, 2025, at 10:30 a.m. ET in New York

The live webcasts will be available in the investor section of the company's website at [www.beamtx.com](http://www.beamtx.com) and will be archived for 60 days following the presentation.

### About Beam Therapeutics

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

### Contacts:

Investors:

Holly Manning

Beam Therapeutics

[hmanning@beamtx.com](mailto:hmanning@beamtx.com)